BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Quintiles, Inc. (QTRN) to Hire 500 in China


1/19/2012 8:21:23 AM

Triangle Business Journal by Chris Bagley, Staff Writer

Quintiles, a Durham-based contract research organization, said Wednesday that it was opening a business process outsourcing and project management center in Dalian.

The new office in northeast China will provide several different types of services to biopharmas, including data management, biostatistics and medical writing for biopharma companies. The office also will support clinical operations for study sites in northeast China.

Quintiles said in a news release that it expects the office to grow to 500 employees in the next several years once all services are fully established. It will be the company’s fourth hub office in Greater China. Quintiles already has offices in Beijing, Shanghai and Hong Kong.

Separately, Quintiles also said Wednesday that it had made a $5 million investment in a British startup that identifies substances associated with various cancers.

The company, Oxford Cancer Biomarkers, has offices in Oxford and Reading, England. Quintiles is the company’s largest shareholder, Quintiles said in a news release Wednesday morning. The University of Oxford and two Oxford scientists are also major shareholders, according to Quintiles. Quintiles spokesman Jay Johnson said Quintiles invested 3 million British Pounds, or about $4.6 million, for a 27.5 percent stake in OCB.

One of the individual owners, Nick La Thangue, is the chairman of cancer biology at the university and the developer of certain technologies to be used by the company. The second, David Kerr, is a professor of cancer medicine and will serve as the company’s chief medical officer.

“Biomarkers” refers to a wide range of cells and organic chemicals that can give key information about associated cancers. Quintiles said the new company will work with Quintiles’ consulting and global laboratory divisions.

“Biomarkers hold great promise to improve trial success rates by identifying patient sub-groups most likely to respond to treatment, increasing the probability of trial success and improving patient safety,” said Ben Cons,

Quintiles’ vice president of corporate development.




   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES